Enliven Therapeutics to present ELVN-001 trial data at EHA congress

May 12, 2026 9:54 AM

Enliven Therapeutics Inc. (NASDAQ: ELVN) announced it will present updated Phase 1 clinical trial data for ELVN-001 in chronic myeloid ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found